查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎 (NASH) 治疗市场 - 增长、未来展望、竞争分析，2023-2031
市场调查报告书
商品编码
1293850

非酒精性脂肪性肝炎 (NASH) 治疗市场 - 增长、未来展望、竞争分析，2023-2031

Nonalcoholic Steatohepatitis (NASH) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格

到 2031 年，非酒精性脂肪性肝炎 (NASH) 药物市场预计将增长 38%。 非酒精性脂肪性肝炎(NASH)是一种影响非酗酒者的疾病，通常被称为“脂肪肝”，因为它会导致与酒精性肝炎难以区分的肝臟损害增加。 肥胖、糖耐量受损和血脂异常是 NASH 患者的主要危险因素。 诊断这种疾病所面临的挑战很大程度上是由于对胰岛素抵抗相关病因的了解不足，尤其是肥胖和代谢综合征。 市场专家表示，许多患者没有症状，与 NASH 相关的实验室检查结果主要是转氨□水平升高。 然而，活检在诊断 NASH 中起着重要作用。 根据美国肝臟基金会的数据，NASH是美国肝移植的第三大原因，数据库显示，超过12%的普通人群会患上NASH，约2.7%的人会因该疾病而患上肝纤维化。 。NASH包括肥胖治疗、胰岛素增敏剂、降脂剂、抗氧化剂和保肝治疗。 减肥治疗 NASH 已在成人中进行了广泛研究，不仅显示出生化效果，而且还显示出组织学改善。

据克利夫兰诊所称，减少膳食碳水化合物，尤其是膳食果糖，已被发现是最有效的，可以改善超重患者的血脂状况。 几种药物正在研究中，包括血清素再摄取抑製剂西布曲明和奥利司他，它们可以减少脂肪吸收。 所有这些都已被证明可以改善肝□水平和脂肪肝的超声征象。 大麻素 1 拮抗剂利莫那班的荟萃分析显示不良事件增加，目前不推荐用于 NAFLD。 在胰岛素增敏剂中，过氧化物□体增殖物激活受体Gamma(PPARg)激动剂(硫格列酮)作为肝脂肪变性的替代标誌物，促进甘油三酯从肝臟和肌肉重新分配到增殖的脂肪细胞，预计可以改善胰岛素抵抗。 智利胃肠病学会和智利肝病学会最近发表的专家评论表明，□格列酮和维生素E的组合是活检证实的NASH患者的一种药物选择，但缺乏关于其长期安全性和有效性的证据。 此外，美国肝病学会的指南将□格列酮列为 NASH 的潜在治疗方法。

北美被确定为 NASH 治疗的最大市场，其次是欧洲。 在北美，肥胖症的增加和糖尿病发病率的增加是支持 NASH 治疗市场的主要因素。 据克利夫兰诊所统计，美国超重患病率已达65%以上，目前美国成年人口中有超过30%患有肥胖症。 其患病率在男性、老年人(40-70 岁)和患有代谢综合征(特别是糖尿病和腹部肥胖)的人群中较高。 儿童肥胖和非酒精性脂肪肝(NAFLD)的患病率相似。 NAFLD 在所有族裔群体中均存在，其中与白人和非裔美国人相比，亚太地区西班牙裔患病率最高，预计在预测期内将以最快的复合年增长率增长。p>

目录

第1章前言

  • 报告内容
    • 报告的目的
    • 目标受众
    • 主要产品
  • 市场细分
  • 调查方法
    • 第一阶段 - 二次调查
    • 第二阶段 - 初步调查
    • 第三阶段 - 专家评审
    • 先决条件
    • 采用的方法

第 2 章执行摘要

第 3 章非酒精性脂肪性肝炎 (NASH) 药物市场：竞争分析

  • 主要供应商的市场定位
  • 供应商采取的策略
  • 主要产业战略
  • 层级分析：2022 年与 2031 年

第 4 章非酒精性脂肪性肝炎 (NASH) 药物市场：宏观分析和市场动态

  • 简介
  • 全球非酒精性脂肪性肝炎 (NASH) 药物市场价值
  • 市场动态
    • 市场驱动因素
    • 市场製约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第 5 章非酒精性脂肪性肝炎 (NASH) 药物市场：按药物类型

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 维生素 E 和□格列酮
    • 卵叶酸 (OCA)
    • 雷非布兰醇
    • 索马鲁□
    • 瑞美隆
    • 亚兰哲
    • 塞尼克里比洛克
    • 其他

第 6 章非酒精性脂肪性肝炎 (NASH) 药物市场：按最终用途分类

  • 市场概况
  • 增长和盈利分析：2022 年与 2031 年
  • 市场细分
    • 医院药房
    • 零售店和专营药店
    • 其他

第 7 章：北美非酒精性脂肪性肝炎 (NASH) 药物市场

  • 市场概况
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按药物类型
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按最终用途分类
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按地区
    • 北美
      • 美国
      • 加拿大
      • 北美其他地区

第 8 章：英国和欧盟非酒精性脂肪性肝炎 (NASH) 药物市场

  • 市场概况
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按药物类型
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按最终用途分类
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按地区
    • 英国和欧盟
      • 英国
      • 德国
      • 西班牙
      • 意大利
      • 法国
      • 其他欧洲地区

第 9 章亚太地区非酒精性脂肪性肝炎 (NASH) 药物市场

  • 市场概况
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按药物类型
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按最终用途分类
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 亚太地区其他地区

第 10 章：拉丁美洲非酒精性脂肪性肝炎 (NASH) 药物市场

  • 市场概况
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按药物类型
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按最终用途分类
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按地区
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第 11 章中东和非洲非酒精性脂肪性肝炎 (NASH) 药物市场

  • 市场概况
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按药物类型
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按最终用途分类
  • 非酒精性脂肪性肝炎 (NASH) 药物市场：按地区
    • 中东和非洲
      • 海湾合作委员会
      • 非洲
      • 其他中东和非洲地区

第12章公司简介

  • Intercept Pharmaceuticals
  • Galmed Pharmaceuticals
  • Inventiva Pharma
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.
Product Code: 137073-05-23

Nonalcoholic Steatohepatitis (NASH) Treatment Market is Expected to Grow at 38% by 2031. Nonalcoholic steatohepatitis (NASH) is also known as 'fatty liver' a disorder that develops in patients who are not alcoholic; mainly causes liver damage that is diagnostically indistinguishable from alcoholic hepatitis. The key risk factors observed in patients suffering from NASH are obesity, glucose intolerance, and dyslipidemia. The challenges that are faced in the diagnosis of the disease are mainly due to poor understanding of pathogenesis linked to insulin resistance especially in obesity or metabolic syndrome. Market experts suggest that most of the patients are asymptomatic and laboratory findings related with NASH mainly include elevations in aminotransferase levels. However, in diagnosis of NASH biopsy pays key role in diagnosis. According to American Liver Foundation, NASH is the third leading cause of liver transplant in the U.S.; database suggests more than 12% of the general population has NASH and approximately 2.7% have advanced liver fibrosis due to the disease. NASH comprises treatment of obesity, insulin-sensitizing agents, lipid-lowering agents, antioxidants, and hepatoprotective therapy. In NASH treatment weight reduction has been widely studied in adults and has shown improvement not only the biochemical results but also the histology.

According to Cleveland Clinic, the reduction of dietary carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve the lipid profile in overweight patients. Several drugs have been studied, including sibutramine, a serotonin reuptake inhibitor, and orlistat, which reduce fat absorption. Both of these have been shown to improve liver enzyme levels and sonographic signs of fatty liver. A meta-analysis of rimonabant, a cannabinoid-1-antagonist, showed that it is associated with increased adverse events and currently it cannot be recommended for NAFLD. In case of insulin-sensitizing agents, peroxisome proliferator-activated receptor gamma (PPARg) agonists (thioglitazones) have projected improvement in insulin resistance, by acting as surrogate marker of fatty liver, and promoting redistribution of triglycerides from the liver and muscle into proliferating adipocytes. According to a recently published review article that was conducted by an expert panel from the "Chilean Gastroenterological Society" and the "Chilean Hepatology Association" suggested that pioglitazone along with vitamin E is a proven pharmacological choice for patients with biopsy-proven NASH, however evidence on its long-term safety and efficacy is lacking. Moreover, the guidelines of the American Association for the Study of Liver Diseases indicate pioglitazone as a possible therapeutic drug for the treatment of NASH.

North America was observed as the largest market for NASH treatment followed by Europe. In North America, the rising prevalence of obesity, and the increasing incidence of diabetes are the key factors assisting the NASH treatment market. According to Cleveland Clinic, The prevalence of overweight persons in the US has risen to more than 65%, and obesity is now present in more than 30% of the adult US population. The prevalence is increased in men, older individuals (those aged 40-70 years), and those with components of the metabolic syndrome especially diabetes and abdominal obesity. The prevalence of childhood obesity and non-alcoholic fatty liver disease (NAFLD) is at similar levels. NAFLD has been observed in all ethnic groups with the highest prevalence seen in Hispanics compared with Caucasians and African Americans Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period.

Key Players Identified for Non-Alcoholic Steatohepatitis (NASH) Treatment Market Include but are Not Limited to:

  • Intercept Pharmaceuticals
  • Galmed Pharmaceuticals
  • Inventiva Pharma
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.

Historical & Forecast Period

This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review.A key data point that enables the estimation of Nonalcoholic Steatohepatitis (NASH) Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Nonalcoholic Steatohepatitis (NASH) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approaches for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Segmentation

Drug Type

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Others

End-use

  • Hospital Pharmacies
  • Retail & Specialty Pharmacies
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • Which is the largest regional market for Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Nonalcoholic Steatohepatitis (NASH) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Nonalcoholic Steatohepatitis (NASH) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
  • 2.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022 (US$ Million)
  • 2.3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022 (US$ Million)
  • 2.4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
  • 3.2. Strategies Adopted by Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Vitamin E and Pioglitazone
    • 5.3.2. Obeticholic Acid (OCA)
    • 5.3.3. Lanifibranor
    • 5.3.4. Semaglutide
    • 5.3.5. Resmetirom
    • 5.3.6. Aramchol
    • 5.3.7. Cenicriviroc
    • 5.3.8. Others

6. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Specialty Pharmacies
    • 6.3.3. Others

7. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 7.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 7.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

8. UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 8.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 8.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

9. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 9.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 9.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

10. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 10.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 10.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

11. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 11.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 11.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Intercept Pharmaceuticals
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Galmed Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Inventiva Pharma
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. AbbVie Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Galectin Therapeutics Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Madrigal Pharmaceuticals
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. NGM Biopharmaceuticals Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Novo Nordisk A/S
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Bristol Myers Squibb
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Gilead Sciences Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 2 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 3 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 4 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 5 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 6 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 7 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 8 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 13 UK Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 14 UK Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 15 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 16 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 17 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 18 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 19 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 20 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 21 France Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 22 France Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 25 Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 26 Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 27 China Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 28 China Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 29 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 30 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 31 India Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 32 India Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 33 Australia Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 34 Australia Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 35 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 36 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 37 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 38 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 39 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 40 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 41 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 42 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 47 GCC Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 48 GCC Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 49 Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 50 Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Quality Assurance
  • FIG. 5 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022
  • FIG. 6 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022
  • FIG. 7 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022
  • FIG. 9 Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Players, 2022
  • FIG. 10 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 11 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022 Vs 2031, %
  • FIG. 12 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022 Vs 2031, %
  • FIG. 13 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 20 France Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 22 China Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 24 India Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031